Targeting interleukin-5 with benralizumab: A novel treatment for drug rash with eosinophilia and systemic symptoms

Emanual Maverakis¹, Antonio Ji-Xu¹, Marie-Charlotte Brüggen^{2

3}

Affiliations

¹ Department of Dermatology, University of California, Davis, Sacramento, California, USA.
² Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
³ Christine Kühne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.

Editorial

Emanual Maverakis et al. Allergy. 2022 Aug.

. 2022 Aug;77(8):2287-2289.

doi: 10.1111/all.15283.

Emanual Maverakis¹, Antonio Ji-Xu¹, Marie-Charlotte Brüggen^{2

3}

¹ Department of Dermatology, University of California, Davis, Sacramento, California, USA.
² Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
³ Christine Kühne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.

No abstract available

Keywords: IL-5; benralizumab; drug rash with eosinophilia and systemic symptoms; mepolizumab; reslizumab.

References

1. Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug Reaction with eosinophilia and systemic symptoms (DReSS): How far have we come? Am J Clin Dermatol. 2019;20(2):217-236. doi:10.1007/s40257-018-00416-4
1. Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med (Lausanne). 2017;4:179. doi:10.3389/fmed.2017.00179
1. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139(6):1026-1032. doi:10.1046/j.1365-2133.1998.02559.x
1. Amini-Vaughan ZJ, Martinez-Moczygemba M, Huston DP. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer. Curr Allergy Asthma Rep. 2012;12(5):402-412. doi:10.1007/s11882-012-0290-3
1. Ange N, Alley S, Fernando SL, Coyle L, Yun J. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(3):1059-1060. doi:10.1016/j.jaip.2017.10.020